Last reviewed · How we verify
Chemotherapy/ADC Regimen
An antibody-drug conjugate (ADC) regimen that delivers cytotoxic chemotherapy payloads to cancer cells via targeted antibody binding to tumor-associated antigens.
An antibody-drug conjugate (ADC) regimen that delivers cytotoxic chemotherapy payloads to cancer cells via targeted antibody binding to tumor-associated antigens. Used for Solid tumors (specific indication not specified in available information).
At a glance
| Generic name | Chemotherapy/ADC Regimen |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Antibody-drug conjugate (ADC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ADCs combine monoclonal antibodies with chemotherapy drugs linked by a cleavable linker. The antibody component binds to specific antigens on cancer cell surfaces, enabling selective delivery of the chemotherapy payload to tumor cells while minimizing systemic exposure. This targeted approach aims to improve efficacy and reduce off-target toxicity compared to conventional chemotherapy.
Approved indications
- Solid tumors (specific indication not specified in available information)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
- Peripheral neuropathy
- Infusion-related reactions
Key clinical trials
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer (PHASE3)
- FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (PHASE3)
- A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer (PHASE2)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer (PHASE2)
- SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer (PHASE3)
- Neoadjuvant Radiotherapy for High-risk UTUC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |